This Company Is Positioned for Healthy Growth

Becoming an integrated health care provider could be a winning strategy for CVS Caremark.

Feb 13, 2014 at 10:37AM

Cvs Image

Source: CVS Caremark.

CVS Caremark (NYSE:CVS) reported earnings for the fourth quarter of 2013 on Tuesday. The numbers were better than expected, and the company raised earnings guidance for the first quarter of 2014. The decision to exit the tobacco business is looking like a smart move in terms of costs versus benefits, and CVS is well positioned for growth in the years ahead.

The numbers
Sales during the quarter increased by 4.6% to $32.8 billion versus $31.4 billion in the same quarter of the prior year; this was above analysts' expectations of $32.6 billion. Revenues in the pharmacy services segment grew by 5.2% to $19.6 billion, while the pharmacy retail division produced a sales increase of 5.6% to $17.2 billion.

Retail pharmacy same-store sales increased 4% over the prior year, with pharmacy same-store sales up 6.8% and front-end same-store sales down 1.9%. The decline in front-end same-store sales was produced by softer traffic, which was partially offset by an increase in basket size.

Income from continuing operations increased 12.4% to $1.3 billion during the quarter. Adjusted earnings per share came in at $1.12, a 15.8% increase versus the fourth quarter in the previous year and beating analysts' estimations by a penny.

The company reaffirmed its earnings guidance for 2014 in the range of $4.36 to $4.50 per share. But CVS raised its guidance for free cash flow during the year to a range of $5.5 billion-$5.8 billion from $5.1 billion-$5.4 billion, and cash flow from operations guidance was increased to between $7.0 billion and $7.3 billion versus a previous guidance of $6.6 billion-$6.9 billion.

Management also raised earnings-per-share guidance for the first quarter of 2014 to between $1.03 and $1.06 versus $0.97 to $1 in the prior estimate. The new guidance is above analysts' estimates for the quarter, currently at $1 per share on average.

A healthy future
The fact that CVS reported strong performance and raised its forward-looking guidance is quite reassuring, especially now that the company could lose some market share in front-end sales after deciding to exit the tobacco business.

Competitor Walgreen (NASDAQ:WBA) recently reported a 3.7% increase in revenue during January on the back of a 2.4% increase in front-end sales. Walgreen has been consistently reporting better front-end sales than CVS over the last several months, so the company seems to be gaining participation in that area. 

Rite Aid (NYSE:RAD) is in a different situation. Though the company is reorganizing its operations, it has not been able to generate consistent sales growth over the last few quarters. Sales for the 47-week period ended Jan. 25, 2014, increased 0.6%, while front-end same-store sales were flat compared to the prior year.

Management estimates CVS will lose $2 billion in revenue -- about $1.5 billion directly from tobacco sales and another $0.5 billion from the rest of those shoppers' baskets -- due to the decision to stop selling tobacco products. This means that CVS could continue losing market share in front-end sales, especially versus Walgreen, which has been performing strongly in that segment lately.

But the company seems quite confident of the fact that expanding its position in health care will more than compensate the negative impact from exiting tobacco in the coming quarters.

In the words of CEO Larry Merlo:

There is a far greater focus emerging on health outcomes, managing chronic disease and reducing costs. And exiting the tobacco category more closely aligns us with the goals of patients, clients and providers positioning our company for future growth. It is also important to recognize that we are doing this from a position of strength. 

MinuteClinic is a compelling growth driver for CVS: The company opened 74 new clinics during the quarter, bringing the total to 800 clinics and growing. The segment delivered a 10% increase in revenue during the quarter despite tough comparisons due to a strong flu season in 2012, and management plans to open at least 150 new clinics in the coming year.  

The company has also signed a 10-year agreement with Cardinal Health, forming the largest generic-drug-sourcing operation in the U.S. The 50-50 joint venture is expected to be operational in July of this year, and it will provide the opportunity to generate higher volume and increased purchasing power in order to reduce costs and efficiently benefit from the generics boom for years to come.

Bottom line
CVS is transforming itself from a simple drugstore to an integrated health care provider, and the recent earnings report shows that the strategy is generating sound financial results. On a long-term basis, betting on health care versus tobacco is a no-brainer considering demand trends and market opportunity, so investors in CVS have nothing to worry about, as the company is strongly positioned for sustained growth.

How to make money from Obamacare
Obamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called "Everything You Need to Know About Obamacare." This FREE guide contains the key information and money-making advice that every American must know. Please click here to access your free copy.

Andrés Cardenal has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers